Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. ZETA

Go back to Sagent Pharmaceuticals (SGNT) Tops Q3 EPS by 1c

Sagent Pharmaceuticals Reports Third Quarter 2015 Financial Results

November 3, 2015 7:01 AM EST

Company Affirms 2015 Full Year Guidance

Allan Oberman Assumes Role of Chief Executive Officer effective September 12, 2015

SCHAUMBURG, Ill., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2015.                                                                                                                                        Third Quarter 2015 and Recent Highlights

Revenue increased 15.1% to $75.2 million driven by base business growth and the October 1, 2014 acquisition of Omega Laboratories Limited (Omega);Gross profit of $24.4 million, or 32.4% of net revenue, inclusive of $0.7 million of non-recurring adjustments;Adjusted EBITDA1 increased 21% to $8.8 million;Settled zoledronic... More